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ABSTRACT
Dedifferentiated chondrosarcoma (DDCS) is a rare disease with a dismal prognosis. 
DDCS consists of two morphologically distinct components: the cartilaginous and 
noncartilaginous components. Whether the two components originate from the same 
progenitor cells has been controversial. Recurrent DDCS commonly displays increased 
proliferation compared with the primary tumor. However, there is no conclusive 
explanation for this mechanism. In this paper, we present two DDCSs in the sellar 
region. Patient 1 exclusively exhibited a noncartilaginous component with a TP53 
frameshift mutation in the pathological specimens from the first surgery. The tumor 
recurred after radiation therapy with an exceedingly increased proliferation index. 
Targeted next-generation sequencing (NGS) revealed the presence of both a TP53 
mutation and a PTEN deletion in the cartilaginous and the noncartilaginous components 
of the recurrent tumor. Fluorescence in situ hybridization and immunostaining confirmed 
reduced DNA copy number and protein levels of the PTEN gene as a result of the PTEN 
deletion. Patient 2 exhibited both cartilaginous and noncartilaginous components in the 
surgical specimens. Targeted NGS of cells from both components showed neither TP53 
nor PTEN mutations, making Patient 2 a naïve TP53 and PTEN control for comparison. 
In conclusion, additional PTEN loss in the background of the TP53 mutation could be 
the cause of increased proliferation capacity in the recurrent tumor.
               Research Paper
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INTRODUCTION
Dedifferentiated chondrosarcoma (DDCS) is 
an uncommon type of chondrosarcoma with a peak 
incidence at 60 to 70 years of age [1]. The most 
frequently affected locations include the femur, 
pelvis, humerus and scapula. Skull involvement is 
extremely rare [1]. Morphologically, there are two 
distinct components. The cartilaginous component 
is characterized by well-differentiated chondrocyte-
like tumor cells. In contrast, the noncartilaginous 
dedifferentiated component is characterized by spindle-
shaped neoplastic cells [2]. DDCS can be further 
categorized into two subtypes based on the relationship 
between the two components. In the classical subtype 
[3, 4], the two components typically exhibit a sharp 
boundary with no transitional zone, whereas a clear 
transitional zone between the two components is 
observed in the non-classical type [4].
The histogenesis of DDCS remains unclear. 
More specifically, the origins of the cartilaginous and 
noncartilaginous components of DDCS remain unknown. 
Two theories exist with regard to the origins of the 
disease. The collision tumor theory [3, 5] states that each 
component originates separately from different progenitor 
cells. In contrast, the competing theory maintains that 
both components originate from the same progenitor cells 
and share common chondrosarcoma-associated somatic 
mutations [4, 6].
There is a dismal prognosis for this disease, for 
which surgical intervention remains the mainstay for 
treatment [1]. The value of chemotherapy remains 
questionable [7]. Previous studies indicate that DDCS 
might recur in the presence or absence of radiation 
therapy [2]. As previously reported [6, 8], the Ki-67 
proliferation index increased when chondrosarcoma 
recurs; however, the mechanism remains unresolved. 
Previous studies [8, 9] have identified several frequent 
genetic mutations in DDCS, including IDH1, IDH2, and 
TP53. TP53 gene deregulation has long been suggested 
as a causative factor for DDCS. The TP53 protein is 
frequently overexpressed in DDCS [4, 10, 11]. However, 
TP53 alone cannot explain the increased Ki-67 index. 
Additional genetic or epigenetic events might account 
for the more rapid progression.
In this paper, we present two patients of DDCS 
in the skull region after radiation therapy. We used 
targeted next-generation sequencing (NGS) technology 
[12-15] to sequence a panel of genes in an attempt to 
discover targetable genetic changes and to decipher the 
pathogenesis of increased proliferation capacity in the 
recurrent tumor.
RESULTS
Medical history, radiographic findings, 
treatment and pathologic findings
Patient 1
This patient was a 28-year-old man who was 
admitted to a local hospital due to headache and diplopia. 
Magnetic resonance imaging (MRI) revealed a 2.8 x 1.9 
x 1.8 cm-sized mass with homogeneous enhancement in 
the sellar region after gadolinium injection (Figure 1A). 
The patient underwent a trans-sphenoidal surgery at 
that hospital. Hematoxylin and eosin (H&E) staining of 
the resected tumor tissue (Patient-1-surgery-1 or P1-S1) 
revealed that the tumor cells had a spindle shape without 
any chondrocytic tumor cells. No tumor cells showed 
S-100 positivity by immunostaining (Figure 1B). No 
positivity was noted for neuron-specific enolase (NSE), 
glial fibrillary acidic protein (GFAP), epithelial membrane 
antigen (EMA), or actin in the tumor cells (data not 
shown). Therefore, no definitive diagnosis, except for a 
spindle cell tumor, was reached in the local hospital.
One month later, MRI detected tumor relapse, 
possibly derived from the remnant tumor cells. The patient 
then underwent a Gamma knife radiosurgery with a dose 
of 1260 cGy to the tumor region (50% isodose curve) at 
the local hospital in an attempt to control the recurrent 
tumor. Unfortunately, 4 months after the Gamma knife 
radiosurgery, the patient exhibited progressive decline 
in visual acuity, severe headaches and blepharoptosis. 
The patient was then transferred to our hospital, and 
MRI demonstrated a 3.0 x 4.8 x 3.5 cm irregular sellar 
cystic mass with ring-enhancement after gadolinium 
injection (Figure 1A). Both fluorodeoxyglucose (FDG) 
and tetraazacyclododecane tetraacetic acid–octreotate 
(DOTATATE) positron emission tomography (PET) images 
exhibited similar ring-shaped tracer uptake (Figure 1C). 
The patient then underwent a trans-sphenoidal surgery. The 
pathological specimen was defined as Patient-1-surgery-2 
(P1-S2). H&E staining revealed both cartilaginous (P1-S2 
cart) and noncartilaginous (P1-S2 noncart) components 
(Figure 1A). A clear transitional zone was noted between 
the two components, resembling the non-classical type 
DDCS. The cartilaginous cells exhibited S-100 positivity 
by immunohistochemical staining (Figure 1B), whereas 
the noncartilaginous component did not (data not shown). 
Both components exhibited vimentin positivity, indicating 
a mesenchymal origin (Figure 1B). CD68 staining was 
positive in a portion of the cells, most likely the intermixed 
histiocytes (Figure 1B). The P1-S2 noncartilaginous 
component exhibited a similar morphology to the tumor 
cells in P1-S1, indicating that P1-S2 might originate from 
the remnant tumor cells from P1-S1.
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Figure 1: A. H&E staining and enhanced MRI of Patient 1. The surgical specimen from the first surgery showed only noncartilaginous 
spindle-shaped tumor cells (P1-S1, upper panel). The surgical specimen from the second surgery exhibited both cartilaginous (P1-S2 cart) 
and noncartilaginous (P1-S2 noncart) neoplastic components (lower panel). B. Representative immunostaining images for S-100 in P1-
S1 as well as S-100, vimentin and CD68 in P1-S2. C. The FDG PET image demonstrated irregular ring-shaped tracer uptake in the sellar 
region (arrow, average SUV 2.58, SUVmax 5.16). Similarly, the DOTATATE PET image highlighted the same ring-shaped somatostatin 
receptor expression in the tumors (arrow, average SUV 0.67, SUVmax 1.04). D. H&E staining and MRI of Patient 2. The surgical specimen 
exhibited both cartilaginous (P2 cart) and noncartilaginous (P2 noncart) components.
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After surgery, although his vision improved, the 
patient died two months later due to disease progression.
Patient 2
This patient was a 37-year-old male patient admitted 
to a local hospital because of headache, coarsened facial 
features and enlarged hands and feet. He had a history 
of removal of a growth hormone-secreting pituitary 
adenoma by a transcranial approach followed by Gamma 
knife radiosurgery (exact dose of radiosurgery not 
documented) ten years previous. At the time of admission, 
the patient complained of severe cephalalgia and vision 
loss in the right eye. This patient was then admitted to 
our hospital. MRI revealed a 5.6 x 5.8 x 5.0 cm irregular 
cystic mass with ring-enhancement, extending to the 
sphenoid sinus, cavernous sinus, clivus, and suprasellar 
region (Figure 1D). The patient underwent a trans-
sphenoidal surgery but died three months later. The 
postoperative pathologic diagnosis was DDCS consisting 
of both cartilaginous (P2 cart) and noncartilaginous 
(P2 noncart) components. A sharp boundary was noted 
with no transitional zone between the cartilaginous and 
noncartilaginous components, resembling the classical 
type (Figure 1D). The noncartilaginous spindled tumor 
cells were negative for MyoD1, myogenin, and desmin 
by immunohistochemical staining (data not shown), 
thus excluding the possibility that the noncartilaginous 
component was a variant of rhabdomyosarcoma [5].
Sequencing and mutation detections
To address the question of whether the P1-S2 tumor 
arose from remnant tumor cells from P1-S1 or arose de 
novo, targeted NGS sequencing was conducted for the P1-S1 
tissue, P1-S2 tissue and peripheral blood cell DNA. It should 
be noted that the P1-S2 tissue that was sequenced consisted 
of both cartilaginous and noncartilaginous components 
without further micro-dissection, as the cartilaginous 
component was interspersed among the noncartilaginous 
component and exhibited clear transitional zones in P1-S2.
Targeted NGS sequencing revealed shared frameshift 
mutations in TP53 c.[835delG] and three other pathogenic 
missense mutations, JAK1 c.[383G>A], MAPK8IP1 
c.[1484C>A] and NTRK1 c.[1925C>T], in both P1-S1 
and P1-S2, indicating that the tumor sample from the 
second surgery (recurrent tumor) was derived from the 
residual tissue from the first tumor. Notably, the mutation 
frequencies in JAK1, NTRK1, and TP53 increased in P1-
S2 compared with P1-S1 (Table 1; Figure 2A, left panel; 
Figure 2B, left panel). No detectable level of IDH1/2 gene 
mutations was found in either P1-S1 or P1-S2, which is 
consistent with previous research demonstrating that not all 
chondrosarcomas harbor such mutations [9, 16].
Furthermore, both components in P1-S2 (60-80%) 
exhibited a considerably increased Ki-67 index compared 
with the non-cartilaginous component (less than 3%) 
in P1-S1 (Figure 2C), indicating that the tumor cells 
exhibited a higher degree of proliferation. P1-S2 also 
harbored other pathogenic mutations, such as missense 
mutations in NCOR1, CREBBP, RPS14 and TERT genes, 
and a loss of copy number in PTEN exons 1-9, indicating 
that additional genetic alterations were acquired during 
disease progression (Figure 2D).
We next asked whether both components from 
Patient 2 harbored mutations in either TP53 or PTEN 
genes. The targeted NGS revealed no pathogenic TP53 
or PTEN gene mutations in either P2 cart or P2 noncart. 
NOTCH4 c.[3562G>A] was predicted to be pathogenic 
and present in both P2 cart and P2 noncart (Table 2; 
Figure 2A, right panel; Figure 2B, right panel). Because 
no peripheral blood DNA was available from this patient 
as a reference control, we could not determine whether the 
shared mutations were germline or somatic. For validation 
purposes, sequencing data from Patient 1 samples (P1-S1 
and P1-S2) were also analyzed by MuTect v1.1.4 and 
Indel by Varscan v2.3.6. The mutations that were called 
were almost identical with those from the standard BGI 
in-house NGS analysis (Supplementary Table 2).
Combined TP53 and PTEN loss likely resulted 
in an increased proliferation index after 
radiotherapy
With regard to the pathogenicity, TP53 c.[835delG] 
was reported in five carcinoma samples in the Catalogue of 
Somatic Mutations in Cancer database. The International 
Agency for Research on Cancer (IARC) database for TP53 
was investigated, and the codons close to this mutation 
were frequently mutated in various types of cancer [17].
The PTEN exon 1-9 region in Patient 1 revealed 
normal reads for P1-S1 but reduced reads for P1-S2 
(Figure 2D), indicating a PTEN loss in P1-S2. To confirm 
this observation, fluorescence in situ hybridization 
(FISH) was performed, which showed both heterozygous 
and homozygous deletions in P1-S2, with 67% of cells 
exhibiting PTEN gene probe loss (11% homozygous 
deletions and 56% heterozygous deletions) in randomly 
selected fields (Figure 2E).
To test whether the TP53 and PTEN alterations were 
related to cell proliferation, we searched for a differently 
tested sample on ‘cBioPortal’ (http://www.cbioportal.org/), 
which is an open-source, web-based analyzer [18, 19]. 
One dataset [20] consisting of over two hundred adult soft 
tissue sarcomas was analyzed, and the gene encoding the 
Ki-67 protein (MKI67) was elevated in 54% of the cases, 
all of which displayed a deregulation of either PTEN or 
TP53 expression (Figure 2F).
Next, we examined the protein levels of PTEN and 
TP53 by immunostaining. Reduced PTEN protein levels 
were detected in immunostaining of P1-S2 (Figure 3A) 
[21]. Both P1-S1 and P1-S2 harbored the same frameshift 
mutation in TP53, which resulted in premature peptide 
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termination and minimal immunostaining for the TP53 
protein (Figure 3A). For Patient 2, neither the cartilaginous 
nor the noncartilaginous components exhibited TP53 or 
PTEN mutations by sequencing. PTEN showed medium-
strong immunostaining intensity in P2 cart and P2 noncart. 
TP53 revealed no immunostaining in either component in 
Patient 2 (Figure 3A). For quality control purposes, an 
adenocarcinoma sample was used as a positive control for 
TP53, and lymphocytes were used as a positive control for 
PTEN (Figure 3A).
The other mutations in Patient 1 were not major 
contributors to disease progression
Because the JAK1 and NTRK1 mutation percentages 
were higher in P1-S2 compared with P1-S1, we were 
interested in whether these two mutations were accountable 
for the increased Ki-67 index. Recent literature has 
highlighted the targeting of receptor tyrosine kinases (RTKs) 
in human chondrosarcoma. One study [22] on human-
derived chondrosarcoma cell lines revealed that targeted 
Table 1: Sequencing data analyzed by the Standard BGI in-house NGS analysis for Patient 1










PRX c.[1687G>A] p.[A563T] Missense 4.27 Not detectable 0.313 VUS
SLC4A1 c.[931C>A] p.[L311I] Missense 5.32 Not detectable 0.477 VUS
FAT3 c.[8657A>G] p.[D2886G] Missense 10 Not detectable 0.319 VUS
SPEN c.[811G>A] p.[G271S] Missense 11.9 Not detectable 0.423 VUS
SIK1 c.[1355C>T] p.[P452L] Missense 16.67 Not detectable 0.523 Pathogenic
NTRK1 c.[1925C>T] p.[A642V] Missense 12.5 17.72 0.540 Pathogenic
JAK1 c.[383G>A] p.[R128H] Missense 23.53 41.48 N/A Pathogenic*
MAPK8IP1 c.[1484C>A] p.[A495D] Missense 35.71 28.02 0.750 Pathogenic
TP53 c.[835delG] p.[G279fs*?] Frameshift 53.12 64.39 N/A Pathogenic
NCOR1 c.[6591G>C] p.[K2197N] Missense Not detectable 3.04 0.523 Pathogenic
RAD50 c.[323A>G] p.[K108R] Missense Not detectable 4.06 0.396 VUS
CREBBP c.[1974C>G] p.[I658M] Missense Not detectable 8.87 0.592 Pathogenic
TSHZ3 c.[1804A>T] p.[M602L] Missense Not detectable 10.36 0.395 VUS
ARHGAP35 c.[3779C>T] p.[P1260L] Missense Not detectable 14.03 0.442 VUS
RAD52 c.[593C>T] p.[P198L] Missense Not detectable 18.02 0.467 VUS
NOTCH1 c.[658G>A] p.[V220M] Missense Not detectable 29.21 0.514 VUS
RPS14 c.[341C>T] p.[S114L] Missense Not detectable 34.89 0.820 Pathogenic
TERT c.[901C>T] p.[R301C] Missense Not detectable 41.02 0.536 Pathogenic
Abbreviations: HGVS: Human Genome Variation Society; P1-S1: Patient-1-surgery-1; P1-S2: Patient-1-surgery-2; VUS: 
variants of unknown significance; N/A: Not available.
* SIFT=0.00, Polyphen-2=1.000 for JAK1: c.[383G>A]
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Figure 2: Targeted NGS showed a combined TP53 and PTEN loss. A. A comparison of the mutation allele frequency in the P1-
S1 (x-axis) versus those in P1-S2 (y-axis) is shown (left panel). A comparison of the mutation allele frequency in the P2 noncart (x-axis) 
versus those in P2 cart (y-axis) is presented (right panel). Shaded areas represent Bayesian posterior probability distributions over mutation 
allele frequency in both samples from the same patients. Gray shading indicates mutation allele frequency distributions having considerable 
uncertainty, with lighter shading indicating greater uncertainty. Mutations of interest are also labeled. B. Oseq targeted sequencing revealed 
both shared and distinct mutations. C. Immunostaining of Ki-67 indexes in surgical specimens from P1-S1, P1-S2 noncart, P1-S2 cart, P2 
noncart and P2 cart. D. Schematic view of copy number estimation from the targeted NGS depth data. The copy number of chr10 in the P1-
S1 sample revealed no copy number changes in the PTEN gene region (locus: 1123~1166) (upper), whereas the copy number of chr10 in the 
P1-S2 sample showed alterations in the PTEN gene exon 1-9 region (lower). E. FISH revealed heterozygous and homozygous deletions in 
the PTEN gene in P1-S2, with organ probes detecting PTEN and green probes detecting the alpha satellite of 10p11.1-q11.1. F. Schematic 
views of the expression levels of MKI67, TP53 and PTEN in a sarcoma dataset.
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RAD54L c.[460C>T] p.[R154W] Missense 3.03 Not detectable 0.749 Pathogenic
NOTCH3 c.[4448G>A] p.[R1483H] Missense 3.06 Not detectable 0.351 VUS
CUL4A c.[1723C>T] p.[H575Y] Missense 3.16 Not detectable 0.657 Pathogenic
TSC1 c.[1039T>C] p.[W347R] Missense 3.24 Not detectable 0.591 Pathogenic
APC c.[1678A>G] p.[K560E] Missense 3.27 Not detectable 0.593 Pathogenic
RAD51D c.[61A>G] p.[R21G] Missense 3.29 Not detectable 0.450 VUS
KMT2A c.[6415T>C] p.[Y2139H] Missense 3.38 Not detectable 0.543 Pathogenic
FOXA2 c.[69+1G>A] N/A Splice-5 3.42 Not detectable N/A VUS
CASP8 c.[319C>T] p.[R107C] Missense 3.45 Not detectable 0.452 VUS
CIC c.[4634C>T] p.[A1545V] Missense 3.52 Not detectable 0.459 VUS
MEN1 c.[598G>A] p.[G200S] Missense 3.62 Not detectable 0.646 Pathogenic
SMC3 c.[1129G>A] p.[A377T] Missense 3.75 Not detectable 0.617 Pathogenic
KIF5B c.[2822G>A] p.[R941H] Missense 4.07 Not detectable 0.649 Pathogenic
SPEN c.[5996A>G] p.[K1999R] Missense 4.32 Not detectable 0.370 VUS
SUZ12 c.[1078C>T] p.[R360C] Missense 5.38 Not detectable 0.448 VUS
ARID1B c.[2764A>T] p.[M922L] Missense 47.88 48.47 0.401 VUS
ARID1B c.[1025C>T] p.[A342V] Missense 45.76 59.26 0.327 VUS
MSH3 c.[178_179 insCCGCAGCGC] p.[63_64insAAP] Cds-indel 31.82 40.58 N/A VUS
NOTCH4 c.[3562G>A] p.[D1188N] Missense 46.77 50.37 0.574 Pathogenic
ATR c.[982A>G] p.[M328V] Missense 87.27 62.56 0.463 VUS
FAT3 c.[10244T>A] p.[L3415H] Missense 96.48 77.2 0.321 VUS
EPHA5 c.[16C>A] p.[P6T] Missense Not detectable 3.17 0.476 VUS
(Continued )
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small molecule inhibitors for RTKs slow tumor cell growth. 
NTRK1 is a transmembrane protein receptor for nerve 
growth factor. After ligand binding, NTRK1 first auto-
phosphorylates at five auto-phosphorylation residues (Y496, 
Y676, Y680, Y681, and Y791) and then phosphorylates 
downstream molecules, such as p44/42 [23, 24]. Activating 
mutations typically result from genomic rearrangements 
in papillary thyroid carcinoma and lung cancer [25], and 
missense mutations rarely lead to overactivation [23]. The 
NTRK1 c.[1925C>T] resulted in a missense mutation of the 
NTRK1 protein p.[A642V] in the intracellular domain of 
the NTRK1 protein. We were able to visualize the spatial 
distances between the four auto-phosphorylated tyrosine 
residues and the amino acid change A642V (Figure 3B); 
the nearest distance of 23.80Å was between Y680 and 
A642V. Thus, the NTRK1 p.[A642V] mutation should not 
directly interfere with the phosphorylation process, and 
the phospho-p44/42 status should be independent of the 
NTRK1 p.[A642V] mutation. Interestingly, phospho-p44/42 
exhibited positivity in approximately 45% of the cells of 
P1-S1. The staining pattern was not homogenous for this 
marker in P1-S2 noncartilaginous component; some areas 
exhibited more tumor cells that were positive for this marker 
than did others. The average percentage of tumor cells 
positive for this marker was 14%. Approximately 55% of 
the cells were positive in the P1-S2 cartilaginous component 
(Figure 3C). This result suggests that phospho-p44/42 might 
not be involved in the tumor progression. In addition, the 
JAK1 c.[383G>A] mutation was previously identified in an 
endometrial carcinoma sample from the Cancer Genome 
Atlas (TCGA) project. Phospho-Stat3, a well-known target 
of the JAK1 protein, exhibited positivity in less than 5-8% of 
cells in the P1-S1, 3% of cells in the P1-S2 noncartilaginous 
component and 6% of cells in the P1-S2 cartilaginous 
component (Figure 3C). This result suggests that the JAK1 
mutation might not be an activating mutation in Patient 1.
We speculated that a TP53-mutated DDCS cancer 
cell might lose its surveillance over genomic instability 
after radiation, which might have induced a PTEN deletion 
in Patient 1. The combined TP53 and PTEN changes 
further promoted tumor progression (Figure 3D).
DISCUSSION
In this paper, we reported two patients of DDCS 
with mutation analysis of selected genes.
The main focus of the current study was to gain 
insight into the pathogenesis of disease progression of 
DDCS. The mechanism that contributes to the disease 
progression from the cartilaginous component to the non-
cartilaginous sarcomatous component remains unclear. 
The present study proposed a mechanism for disease 
progression in which combined TP53 and PTEN changes 
promote tumor progression in DDCS. Indeed, PTEN 
gene mutations are rare in chondrosarcoma, and Lin et 
al reported that a PTEN mutation was detected in only 
one out of forty chondrosarcoma cases [26]. Alterations 
in the PTEN gene are frequently observed after radiation 
when TP53 is null or heterozygous in lymphoma [27]. 
TP53 mutation or loss has been implicated in other types 
of sarcoma [28-30]. The concurrent loss of function in 
PTEN and TP53 provided an explanation for rapid disease 
progression at the time of cancer recurrence for other 
tumors, which was also the case for invasive bladder cancer 
[31]. In addition, RTK has been reported to be activated 
in this type of tumor [22]. However, the NTRK1 mutation 














FLT4 c.[3106A>G] p.[R1036G] Missense Not detectable 3.41 0.542 Pathogenic
NOTCH3 c.[458G>A] p.[R153H] Missense Not detectable 3.52 0.530 Pathogenic
MAPK1 c.[76A>G] p.[T26A] Missense Not detectable 3.57 0.492 VUS
HDAC6 c.[2764C>T] p.[Q922*] Nonsense Not detectable 3.7 N/A VUS
*
CUL4B c.[830A>G] p.[E277G] Missense Not detectable 4.9 0.527 Pathogenic
MED12 c.[5746C>T] p.[Q1916*] Nonsense Not detectable 6.25 N/A Pathogenic
Abbreviations: HGVS: Human Genome Variation Society; P2 cart: Patient 2 cartilaginous component; P2 noncart: Patient 2 
noncartilaginous component; VUS: variants of unknown significance; N/A: Not available.
* SIFT=0.25, Polyphen-2=0.557 for HDAC6: c.[2764C>T]
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Both patients recurred after radiation therapy. 
Indeed, only a few cases of DDCS in the skull base have 
been reported, including two patients with a history of 
prior radiation therapy to the maxillary and frontal bone 
regions years before the onset of DDCS [9, 32]. The 
first issue is whether radiation ‘induced’ the occurrence 
of the dedifferentiated component in DDCS. Our study 
cannot answer this question with certainty. In general, 
conventional skull base chondrosarcomas respond well 
to surgery combined with radiation therapy [33, 34]. 
However, if the diagnosis is DDCS, then prognosis is poor 
Indeed, it is very challenging for a pathologist to make 
the diagnosis of DDCS when the cartilaginous component 
is absent or unavailable. Patient 1 exhibited nearly no 
morphological relevance to chondrosarcoma in the first 
surgery, possibly due to incomplete surgical resection, 
with only spindle-shaped tumor cells.
Previous studies have suggested that the 
noncartilaginous component might derive from the 
cartilaginous component with additional mutations. Ropke 
et al reported that LOHs of the TP53 and RB genes were 
exclusively found in the noncartilaginous component [8]. 
Terek et al reported that likely-mutated TP53 protein was 
accumulated in the noncartilaginous but not cartilaginous 
components of DDCS [35]. Grote et al reported a TP53 
mutation that occurred exclusively in the noncartilaginous 
Figure 3: Combined TP53 and PTEN alterations accounted for disease progression. A. Immunostaining of PTEN and 
TP53 in surgical specimens from P1-S1, P1-S2 noncartilaginous component (P1-S2 noncart), P1-S2 cartilaginous component (P1-S2 
cart), Patient 2 noncartilaginous component (P2 noncart) and Patient 2 cartilaginous component (P2 cart) (left panel). Positive controls 
for TP53 and PTEN were adenocarcinoma and endometrial tumors, respectively (right panel). B. Three-dimensional (3D) structural view 
of the NTRK1 protein. The distance from mutated the A642V to the Y676, Y680, Y681, and Y791 residues were 25.48 Å, 23.80 Å, 25.83 
Å, and 31.91 Å, respectively. C. Immunostaining of phospho-p44/42 (Thr202/204) and phospho-Stat3 (Tyr705). D. Proposed schematic 
illustration of the disease progression due to the combined TP53 and PTEN changes.
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component [11]. Simms et al demonstrated increased TP53 
staining in the spindle-cell portion of eight DDCS cases, 
whereas all of the cartilaginous components showed weak 
or no staining [36]. In our study, the non-cartilaginous 
component of P1-S1 shared common mutations in TP53, 
JAK1, MAPK8IP1 and NTRK1 in the mixed sample of 
P1-S2. However, the P1-S2 sample exhibited additional 
mutations in other genes, including a PTEN deletion. 
The TP53 immunostaining was negative for both Patient 
1 and Patient 2. Patient 1 had a frameshift mutation in 
the TP53 gene encoding pre-truncated TP53 proteins, 
which explains the negative TP53 immunostaining for 
this patient. For Patient 2, we speculate that the wild-type 
TP53 protein was low in abundance in comparison with 
the positive control and below the detection threshold of 
TP53 immunostaining in the current setting.
One major limitation of our study was that the 
number of sequenced genes was limited. The targeted 
NGS only included the predefined exonic regions of 
508 genes. Therefore, epigenetic changes, genomic 
rearrangement, and genes outside of that panel could not 
be detected. Indeed, one study suggested that both genetic 
and epigenetic alterations might occur in DDCS [8].
In conclusion, the present study provided evidence 
that the rapid progression and increased Ki-67 index likely 
resulted from the concurrent mutations in TP53 and PTEN 
genes. The multiple gene alternations detected in the 
present study suggest that there might be other molecular 
pathways contributing the progression of DDCS as well.
MATERIALS AND METHODS
Ethical approval
The study protocol was reviewed and approved by 
the Ethnical Committee of Peking Union Medical College 
Hospital. The two patients provided signed informed 
consent to approve the portion of the surgical specimens 
for research purposes.
18F-FDG and 68Ga DOTATATE PET/CT imaging
One patient was IV-injected with 370 MBq of 
18F-FDG and 120 MBq of 68Ga DOTATATE (a novel 
somatostatin analog), respectively. One hour later, the 
PET/CT images were acquired using a Siemens Biograph 
TruePoint True V PET/CT (Knoxville, TN, USA) 
combining 64-slice CT with a supine position.
Targeted NGS and validation
Tumor DNA was extracted from formalin-fixed 
paraffin-embedded (FFPE) samples and fresh frozen 
samples using the QIAamp DNA FFPE Tissue Kit and the 
DNEasy Blood and Tissue Extraction Kit (Qiagen, Hilden, 
Germany), respectively, according to the manufacturer's 
instructions. All FFPE and fresh frozen tissue samples 
underwent H&E staining and were reviewed by a 
pathologist to ensure > 70% tumor content. DNA purity 
and concentration were assessed using a NanoDrop2000 
spectrophotometer (Thermo Fisher Scientific, Florida, 
USA); DNA quality was assessed by agarose gel 
electrophoresis.
Library construction was performed as 
previously described using 1 μg of DNA sheared by 
an ultrasonoscope to generate fragments with a peak 
length of 250 bps, followed by end repair, A tailing and 
ligation to the Illumina-indexed adapters according 
to the standard library construction protocol. Target 
enrichment was performed on a custom sequence capture-
probe (Nimblegen, USA), which targeted 7,708 exons of 
508 cancer-related genes and 78 introns from 19 genes 
recurrently rearranged in solid tumors, representing 
approximately 1.7 Mb of the human genome in total 
(Supplementary Table 1). Sequencing was performed with 
2 x 101-bp paired-end reads and an 8-bp index read on an 
Illumina Hiseq 2500 platform (Illumina, San Diego, USA) 
using the manufacturer’s protocols.
Primary sequence data were first processed by 
filtering adaptor sequences and removing low-quality 
reads using the SOAPnuke software developed by BGI 
and then aligned to build hg19 of the NCBI reference 
genome assembly using the BWA aligner v0.6.2-r126. 
Polymerase chain reaction (PCR) duplicate reads were 
removed by PICARD v1.98. Local realignment, base 
quality score recalibration was performed using GATK 
v2.3-9, and poorly mapped reads were removed based on 
the recalibration result. SNVs were detected by Standard 
BGI in-house NGS analysis SOMATK-SNV (developed 
by BGI, manuscript in preparation), and Indels (small 
insertions and deletions) were detected by SOMATK-
INDEL (developed by BGI, manuscript in preparation). 
Copy number variation (CNV) calling was performed by 
CONTRA v2.0.4. Known SNPs and Indels obtained from 
the 1000 Genomes project were discarded. The remaining 
variants were subdivided into four categories: (1) variants 
that were previously reported to be deleterious; (2) 
variants that were likely to be gene-disrupting, including 
nonsense and splicing mutations and frameshift caused 
by Indels; (3) missense mutations that were judged to be 
pathogenic by Condel software [37] and those could not 
be predicted by Condel will be predicted by both SIFT and 
PolyPhen-2 [38, 39] (SIFT score < 0.05 AND Polyphen-2 
score > 0.85); (4) the remaining variants that were 
considered as variants of unknown significance (VUS). 
The first three categories were defined as pathogenic. 
Sanger bidirectional sequencing confirmed the detected 
mutations of NTRK1, JAK1, MAPK8IP1 and TP53 in P1-
S2. For comparison, SNVs were also called by MuTect 
v1.1.4 [40], and Indels were called by Varscan v2.3.6 [41].
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Pathological evaluation and 
immunohistochemistry staining
The FFPE specimens were serially sectioned to 
generate 4-μm unstained slides for H&E staining and 
immunohistochemical studies with the following markers: 
S-100 (Abcam, Cat #: ab34686, 1:250), vimentin (Abcam, 
Cat #: ab92547, 1:250), CD68 (Abcam, Cat #: ab955, 
1:200), PTEN (Cell Signaling Technology, Cat #: 9559, 
1:100), TP53 (Abcam, Cat #: ab4060, 1:100), Ki-67 (Cell 
Signaling Technology, Cat #: 9027 1:200), phospho-p44/42 
(Thr202/Tyr204) (Cell Signaling, Cat #: 9101, 1:50), and 
phospho-Stat3 (Tyr705) (Cell Signaling Technology, Cat 
#: 9145, 1:400). The immunohistochemical staining was 
performed according to the standardized protocols [42, 43].
FISH test for PTEN gene loss
The PTEN loss was confirmed by FISH (Vysis LSI 
PTEN SpectrumOrange/CEP 10 SpectrumGreen Probes 
Abbott, 07j74-001) with organ probes covering a 368-
kb length of chromosome 10q23, including the regions 
encoding PTEN, and green probes covering CEP 10 of 
alpha satellite of 10p11.1-q11.1 DNA.
Amino acid distance estimation from the protein 
3D structure
The 3D protein structure file was downloaded from 
the RCSB Protein Data Bank. The distance was measured 
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